Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform – The integrated aPROMISE solution to be demonstrated on Siemens Healthineers’ syngo.via platform at the SNMMI annual meeting

Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform – The integrated aPROMISE solution to be demonstrated on Siemens Healthineers’ syngo.via platform at the SNMMI annual meeting aPROMISE is a deep learning-enabled, FDA-cleared...

EXINI executes agreement with INmune Bio for Phase I/II trial

CaRe PC is an open label Phase I/II trial that will test up to three doses of INKmune™ in men with mCRPC. INKmune™ is given as out-patient therapy via intravenous infusion three times in the first two weeks of treatment (days 1, 8 and 15). The patient is followed for...
New version released of PYLARIFY AI® (aPROMISE)

New version released of PYLARIFY AI® (aPROMISE)

We have now released a new version of PYLARIFY AI® for prostate cancer analysis. The new version include features such as: Parallel Study Review Select all suggested hotspots CT Measurement Tool Configurable Crosshair User Specific Settings Report Improvements...

EXINI Diagnostics AB, a Lantheus company (EXINI), announced today a ‘License and Development’ agreement with Curium, a world leader in nuclear medicine , to customize EXINI’s artificial intelligence (AI) platform for use in Europe.

Under the terms of the agreement, EXINI’s deep learning platform will be tailored to meet the specific needs of the European market. The clinical value proposition of the platform is to increase the efficiency and reproducibility of PSMA PET/CT image assessments in...